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Atopic dermatitis (AD) is a chronic inflammatory skin disease prone to relapse, having both 
genetic and environmental factors (e.g. allergens) as underlying causes for its development. 
The use of allergen specific immunotherapy (ASIT) has been restricted to insect venom 
allergy, allergic rhinitis and mild extrinsic asthma; however a few contradicting results are 
available on the use of ASIT in AD. Our aim was to analyze the effect of ASIT on clinical 
and subclinical variables in patients sensitized by house dust mite and suffering from both 
allergic rhinitis and AD. We examined the patients clinical (physical status, disease specific 
questionnaire), immunological laboratory (defining regulatory and effector T cells and also 
blood dendritic cells – flow cytometry; determining serum allergen specific IgE levels – 
ELISA; atopy patch test, prick test) as well as skin barrier (specifying Filaggrin mutation – 
molecular genetics; determining serum TSLP levels – ELISA; measuring TEWL – 
Tewameter) parameters prior to and during the ASIT treatment in comparison with diseased 
control groups. As a result of ASIT the measured clinical and skin barrier variables displayed 
improvement compared to the initial values as well as to the control group, although the 
differences were not significant. However when only patients without filaggrin mutation 
where compared, the ASIT treated patients showed significant improvement in barrier 
(TEWL) function (38,96+17,42 g/m
2
h vs. 19,97+2,077 g/m
2
h; p=0,0357). This result 
predispose that the modified immune status may improve the skin barrier in the mild-to-
moderate patients without filaggrin mutation. Perhaps this AD population may benefit of 
ASIT. There is an intricate pathogenesis underlying AD, which requires a complex approach 
in therapy. Additionally to the previously described immunological changes attributed to 
ASIT, analysis of other physicochemical barrier parameters is crucial. 
